Shots:

• Biogen will receive an exclusive license to develop the product worldwide and will be responsible for all US FDA required IND enabling studies- clinical development- and commercialization
• The companies collaborated to develop a therapy for IRDs due to mutations in the PRPF31 gene. Research performed at Harvard Ophthalmology demonstrated that AAV-mediated gene augmentation therapy for PRPF31 can restore normal function to mutant RPE cells
• The agreement emphasizes Biogen’s commitment to the acquisition of Nightstar Therapeutics in 2019 and its active clinical trials targeting different genetic forms of IRD. Biogen will leverage its pre/ clinical experience to PRPF31 program

Click here to read full press release/ article

 | Ref: Newswise | Image:Biogen